Biogen Vumerity Receives Full US Approval, But GI Comparison With Tecfidera Must Wait
Label offers little differentiation from Tecfidera, but head-to-head trial with custom-designed patient-reported outcome could make case for gastrointestinal tolerability advantage.
You may also be interested in...
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.
US FDA approval of the Alzheimer's drug may be uncertain, but Biogen will be investing substantially behind a commercial buildout this year.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.